EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Aptamer sgc8-Modified PAMAM Nanoparticles for Targeted siRNA Delivery to Inhibit BCL11B in T-Cell Acute Lymphoblastic Leukemia

Xiangbo Zeng, Dingrui Nie, Zhen Liu iD, Xueting Peng, Xianfeng Wang, Kangjie Qiu, Shuxin Zhong, Ziwei Liao, Xianfeng Zha, Yangqiu Li iD, Chengwu Zeng iD

International Journal of Nanomedicine · 2024-11 · Volume 19 · 12297-12309

DOI: 10.2147/ijn.s477597 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2024-11. Verfasst von Xiangbo Zeng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, …. Hauptthemen laut MEDLINE: RNA, Small Interfering, Dendrimers, Aptamers, Nucleotide, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

T-cell acute lymphoblastic leukemia (T-ALL) is a malignant hematological disease with limited targeted therapy options. Overexpression of B-cell lymphoma/leukemia 11B is frequently observed in T-ALL and contributes to leukemogenesis. Knockdown of BCL11B inhibits T-ALL cell proliferation and induces apoptosis, making it a potential therapeutic target. However, the clinical application of siRNA therapies is hindered by challenges such as poor delivery efficiency and limited clinical outcomes.

Methods

We developed a targeted delivery system for BCL11B siRNA (siBCL11B) using generation 5 polyamidoamine (G5-PAMAM) dendrimers conjugated with the sgc8 aptamer, which specifically binds to the T-ALL cell membrane protein PTK7. This nanoparticle, designated G5-sgc8-siBCL11B, was designed to selectively deliver siRNA to T-ALL cells. In vitro and in vivo experiments were conducted to evaluate its therapeutic efficacy and safety.

Results

We demonstrate that sgc8-conjugated siBCL11B nanoparticles selectively and efficiently target BCL11B-overexpressing T-ALL cells, significantly inhibiting cell viability and promoting apoptosis while exhibiting minimal impact on the viability of normal T cells. In T-ALL mouse model studies, G5-sgc8-siBCL11B and G5-siBCL11B significantly inhibited the progression of T-ALL in vivo, extending the survival of mice compared to the control (CTR), G5, and G5-sgc8 groups. Although there was no significant difference in survival between the G5-sgc8-siBCL11B and G5-siBCL11B groups, a trend towards improved survival was observed (p = 0.0993).

Conclusion

The G5-sgc8-siBCL11B nanoparticle system demonstrated efficient delivery and significant therapeutic efficacy, highlighting its potential as a promising novel approach for the treatment of T-ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Small InterferingDendrimersAptamers, NucleotidePrecursor T-Cell Lymphoblastic Leukemia-LymphomaNanoparticlesRepressor ProteinsAnimalsHumansCell Line, TumorMiceApoptosisCell SurvivalXenograft Model Antitumor AssaysCell ProliferationCell Adhesion MoleculesReceptor Protein-Tyrosine KinasesTumor Suppressor Proteins

Stichwörter der Autor:innen

BCL11BPAMAMT-ALLaptamersgc8siBCL11B

Substanzen

RNA, Small InterferingDendrimersAptamers, NucleotidePAMAM StarburstRepressor ProteinsBCL11B protein, humanPTK7 protein, humanCell Adhesion MoleculesReceptor Protein-Tyrosine KinasesTumor Suppressor Proteins

Autor:innen und Institutionen

  • Key Laboratory for Regenerative Medicine of Ministry of Education, Institute of Hematology, School of Medicine, Jinan University, Guangzhou, 510632, People's Republic of China.
  • Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, People's Republic of China.
  • Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
  • Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510180, People's Republic of China.
  • Department of Clinical Laboratory, First Affiliated Hospital, Jinan University, Guangzhou, 510632, People's Republic of China.

ORCID-Profile: Zhen Liu, Yangqiu Li, Chengwu Zeng

Zitieren

APA

Zeng, X., Nie, D., Liu, Z., Peng, X., Wang, X., Qiu, K., Zhong, S., Liao, Z., Zha, X., Li, Y., & Zeng, C. (2024). Aptamer sgc8-Modified PAMAM Nanoparticles for Targeted siRNA Delivery to Inhibit BCL11B in T-Cell Acute Lymphoblastic Leukemia. International Journal of Nanomedicine, Volume 19, 12297-12309. https://doi.org/10.2147/ijn.s477597

Vancouver

Zeng X, Nie D, Liu Z, Peng X, Wang X, Qiu K, et al. Aptamer sgc8-Modified PAMAM Nanoparticles for Targeted siRNA Delivery to Inhibit BCL11B in T-Cell Acute Lymphoblastic Leukemia. International Journal of Nanomedicine. 2024;Volume 19:12297-12309. doi:10.2147/ijn.s477597

BibTeX
@article{Zeng2024,
  author = {Zeng, Xiangbo and Nie, Dingrui and Liu, Zhen and Peng, Xueting and Wang, Xianfeng and Qiu, Kangjie and Zhong, Shuxin and Liao, Ziwei and Zha, Xianfeng and Li, Yangqiu and Zeng, Chengwu},
  title = {Aptamer sgc8-Modified PAMAM Nanoparticles for Targeted siRNA Delivery to Inhibit BCL11B in T-Cell Acute Lymphoblastic Leukemia},
  journal = {International Journal of Nanomedicine},
  year = {2024},
  volume = {Volume 19},
  pages = {12297--12309},
  doi = {10.2147/ijn.s477597}
}
Kostenlos starten →